Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tiffani C. Chance has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner and 1 distinct art unit. The current patent activity is concentrated on a single biotechnological matter. This focused approach allows for a dedicated prosecution strategy that addresses the specific technical requirements of the 1 distinct art unit involved.
WESTON, ALYSSA G is the busiest examiner for the portfolio, managing 1 pending office action. This single matter constitutes the entire pending workload for the company. The prosecution timeline will be determined by the specific caseload and requirements of this 1 examiner. Practitioners should tailor their legal arguments to the specific examination style of WESTON, ALYSSA G to advance the application.
With only 1 pending office action, the company does not have to manage multiple examiners or art units. However, this also means that the company's entire active patent presence is dependent on the outcome of this single matter. Practitioners should carefully review the standards of the Biotechnology & Pharmaceuticals technology area to ensure that the application is positioned for a favorable review by the 1 distinct examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTON, ALYSSA G | 1 | 59.2% | +50.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037478 | EXTRACELLULAR VESICLES DERIVED FROM CARDIOSPHERE-DERIVED CELLS AS ANTI-SHOCK THERAPEUTICS | WESTON, ALYSSA G | 7d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037478 | EXTRACELLULAR VESICLES DERIVED FROM CARDIOSPHERE-DERIVED CELLS AS ANTI-SHOCK THERAPEUTICS | WESTON, ALYSSA G | 7d |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037478 | EXTRACELLULAR VESICLES DERIVED FROM CARDIOSPHERE-DERIVED CELLS AS ANTI-SHOCK THERAPEUTICS | WESTON, ALYSSA G | 1633 | §102§103 | Final Rejection | 7d | Pending | Nov 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTiffani C. Chance has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Alyssa G Weston has the most, with 1 of Tiffani C. Chance's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.